Source: Brazilian Journal of Pharmaceutical Sciences. Conference titles: Pharmaceutical Science and Technology Meeting. Unidade: FCF
Subjects: ARTERIOSCLEROSE, CAMUNDONGOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CÉSAR, Fernanda Andrade de et al. Novel thiazolidine-2,4-diones inhibit atherosclerotic lesion progression in ldl receptor deficient mice. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo. . Acesso em: 09 maio 2024. , 2012APA
César, F. A. de, Rudnicki, M., Saito, C., Gadino, S., Pitta, I., Lima, M. do C. A. de, & Abdalla, D. S. P. (2012). Novel thiazolidine-2,4-diones inhibit atherosclerotic lesion progression in ldl receptor deficient mice. Brazilian Journal of Pharmaceutical Sciences. São Paulo: Faculdade de Ciências Farmacêuticas, Universidade de São Paulo.NLM
César FA de, Rudnicki M, Saito C, Gadino S, Pitta I, Lima M do CA de, Abdalla DSP. Novel thiazolidine-2,4-diones inhibit atherosclerotic lesion progression in ldl receptor deficient mice. Brazilian Journal of Pharmaceutical Sciences. 2012 ; 48 49 res. FCF094.[citado 2024 maio 09 ]Vancouver
César FA de, Rudnicki M, Saito C, Gadino S, Pitta I, Lima M do CA de, Abdalla DSP. Novel thiazolidine-2,4-diones inhibit atherosclerotic lesion progression in ldl receptor deficient mice. Brazilian Journal of Pharmaceutical Sciences. 2012 ; 48 49 res. FCF094.[citado 2024 maio 09 ]